Clinical Trials
16
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 195
- Registration Number
- NCT06836063
Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SUVN-I6107 In Healthy Participants
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 64
- Registration Number
- NCT06705088
- Locations
- 🇺🇸
Clinical Research Site, San Antonio, Texas, United States
Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 41
- Registration Number
- NCT06126497
- Locations
- 🇺🇸
Clinical Innovations, Inc, Bellflower, California, United States
🇺🇸NRC Research Institute, Orange, California, United States
🇺🇸Collaborative Neuroscience Research, LLC, Torrance, California, United States
Expanded Access to SUVN-G3031 (Samelisant) for the Treatment of Subjects With Narcolepsy
- Conditions
- Narcolepsy
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Suven Life Sciences Limited
- Registration Number
- NCT05530447
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
- Conditions
- AgitationAlzheimer's Type Dementia
- Interventions
- Drug: Masupirdine 50 mgDrug: PlaceboDrug: Masupirdine 100 mg
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 375
- Registration Number
- NCT05397639
- Locations
- 🇺🇸
Advanced Research Center, Inc., Anaheim, California, United States
🇺🇸ATP Clinical Research, Inc., Costa Mesa, California, United States
🇺🇸Leading Edge Research LA, LLC, Encino, California, United States
- Prev
- 1
- 2
- 3
- Next
News
Anthem Biosciences Launches ₹3,395 Crore IPO as Contract Research Organization Targets Public Markets
Anthem Biosciences, a Contract Research, Development, and Manufacturing Organization (CRDMO), is launching a ₹3,395 crore IPO from July 14-16 with shares priced at ₹540-570 each.
Suven Life Sciences Initiates Phase 1 Trial of SUVN-I6107 for Cognitive Disorders
• Suven Life Sciences has dosed the first subjects in a Phase 1 clinical trial of SUVN-I6107 for cognitive disorders. • The Phase 1 trial is a randomized, double-blind, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. • SUVN-I6107 is a novel, potent, and selective muscarinic M1 positive allosteric modulator, showing efficacy in animal models. • The trial is being conducted in the US under FDA acceptance of an Investigational New Drug application.
Suven Life Sciences' Ropanicant Shows Positive Phase 2a Results for Major Depressive Disorder
• Suven Life Sciences announced positive results from its Phase 2a proof-of-concept study of Ropanicant (SUVN-911) in patients with moderate to severe Major Depressive Disorder (MDD). • Ropanicant, an α4β2 nicotinic acetylcholine receptor (nAChR) antagonist, demonstrated promising safety and efficacy outcomes in the open-label Phase 2a study. • Suven plans to advance Ropanicant into a double-blind, placebo-controlled Phase 2b clinical study in MDD patients, anticipated to start in early 2025. • The company will present these findings at the upcoming Neuroscience 2024 conference, highlighting its portfolio of new chemical entities.